3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
20
Carcinoma, Renal Cell
12
Colorectal Neoplasms
10
Kidney Neoplasms
8
Ovarian Neoplasms
6
Neoplasms
5
Carcinoma, Transitional Cell
5
Urethral Neoplasms
4
Stomach Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Urothelial Carcinoma of the Bladder
1
Interventions
padeliporfin
5
Mitomycin
3
pembrolizumab
2
alectinib
2
Standard of Care
2
Pluvicto
2
Nivolumab
2
Cisplatin
2
Abiraterone Acetate
2
valrubicin
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
osimertinib
1
onapristone
1
olaparib
1
gallium 68 PSMA-11
1
enzalutamide
1
enfortumab vedotin
1
darolutamide
1
cobimetinib
1
apalutamide
1
abiraterone
1
Therapeutics
1
Taxes
1
Sunitinib
1
Radiation Dose Hypofractionation
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Fluorouracil
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled